share_log

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma 宣布在 AACR 2023 年年会上接受摘要,强调 HSB-510 是治疗实体瘤和白血病的新型双功能抑制剂
Benzinga Real-time News ·  2023/02/08 07:18

An abstract highlighting the progress of the Quatramer-based dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, and navitoclax (BCL-XL/BCL-2 inhibitor) has been scheduled for presentation in a Poster Session at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida and will be published in the online Proceedings of the AACR.

一份重点介绍基于Quatramer的双靶向pi3-kΔ/HDac6抑制剂 HSB-510 和navitoclax(BCL-XL/BCL-2抑制剂)进展的摘要已计划在佛罗里达州奥兰多举行的2023年美国癌症研究协会(AACR)年会的海报会上发表,并将发表在AACR的在线会议记录上。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发